|
US4816567A
(en)
|
1983-04-08 |
1989-03-28 |
Genentech, Inc. |
Recombinant immunoglobin preparations
|
|
US5567584A
(en)
|
1988-01-22 |
1996-10-22 |
Zymogenetics, Inc. |
Methods of using biologically active dimerized polypeptide fusions to detect PDGF
|
|
US20020099179A1
(en)
|
1989-12-21 |
2002-07-25 |
Linda K. Jolliffe |
Cdr-grafted antibodies
|
|
DK261490D0
(da)
|
1990-10-31 |
1990-10-31 |
Novo Nordisk As |
New pharmaceutical compound
|
|
US6165467A
(en)
|
1991-07-20 |
2000-12-26 |
Yoshihide Hagiwara |
Stabilized human monoclonal antibody preparation
|
|
US5789192A
(en)
|
1992-12-10 |
1998-08-04 |
Schering Corporation |
Mammalian receptors for interleukin-10 (IL-10)
|
|
US6685940B2
(en)
|
1995-07-27 |
2004-02-03 |
Genentech, Inc. |
Protein formulation
|
|
JP3681206B2
(ja)
|
1995-12-26 |
2005-08-10 |
株式会社三菱化学ヤトロン |
抗ファクターＸａ・ティシュファクターパスウェイインヒビター複合体モノクローナル抗体及びその使用
|
|
CN1270389C
(zh)
|
1996-06-28 |
2006-08-16 |
精工爱普生株式会社 |
薄膜晶体管及其制造方法
|
|
EP2065396A1
(en)
|
1996-08-30 |
2009-06-03 |
Human Genome Sciences, Inc. |
Interleukin-19
|
|
US5985614A
(en)
|
1996-08-30 |
1999-11-16 |
Human Genome Sciences, Inc. |
Polynucleotides encoding interleukin-19
|
|
US5945511A
(en)
|
1997-02-20 |
1999-08-31 |
Zymogenetics, Inc. |
Class II cytokine receptor
|
|
EP0979102A4
(en)
|
1997-04-30 |
2005-11-23 |
Enzon Inc |
DETAILED POLYPEPTIDE MODIFIED BY POLYALKYLENE OXIDE
|
|
JP2001510035A
(ja)
|
1997-07-16 |
2001-07-31 |
ヒューマン ジノーム サイエンシーズ， インコーポレイテッド |
インターロイキン−２０
|
|
US6486301B1
(en)
|
1997-07-16 |
2002-11-26 |
Human Genome Sciences, Inc. |
Interleukin-20
|
|
WO1999007740A2
(en)
|
1997-08-06 |
1999-02-18 |
Zymogenetics, Inc. |
Lipocalin homologs
|
|
US6576743B1
(en)
|
1997-11-26 |
2003-06-10 |
Zymogenetics, Inc. |
Mammalian cytokine-like polypeptide-10
|
|
EP1047781B1
(en)
|
1998-01-23 |
2004-07-28 |
Immunex Corporation |
Il-18 receptors
|
|
WO1999046379A2
(en)
|
1998-03-09 |
1999-09-16 |
Schering Corporation |
Human receptor proteins; related reagents and methods
|
|
ES2312205T3
(es)
|
1998-03-10 |
2009-02-16 |
Genentech, Inc. |
Nuevo polipeptido y acidos nucleicos que lo codifican.
|
|
US7198789B2
(en)
|
1998-03-17 |
2007-04-03 |
Genetics Institute, Llc |
Methods and compositions for modulating interleukin-21 receptor activity
|
|
CN1233476A
(zh)
|
1998-04-24 |
1999-11-03 |
陆道培 |
治疗急性白血病的药物及其制备方法
|
|
AU5203199A
(en)
|
1998-05-26 |
1999-12-13 |
Procter & Gamble Company, The |
Chimeric molecules comprising an extracellular ligand binding domain of a receptor and an ige fc or constant region, and their use in an assay system
|
|
AU4411699A
(en)
|
1998-06-05 |
1999-12-20 |
Human Genome Sciences, Inc. |
Interferon receptor hkaef92
|
|
US6936697B2
(en)
|
1998-09-01 |
2005-08-30 |
Genentech, Inc. |
Secreted and transmembrane polypeptides and nucleic acids encoding the same
|
|
JP2002524514A
(ja)
*
|
1998-09-17 |
2002-08-06 |
イーライ・リリー・アンド・カンパニー |
タンパク質製剤
|
|
US6451286B1
(en)
*
|
1998-12-21 |
2002-09-17 |
Generex Pharmaceuticals Incorporated |
Pharmaceutical compositions for buccal and pulmonary administration comprising an alkali metal alkyl sulfate and at least three micelle-forming compounds
|
|
US7087215B2
(en)
*
|
1998-12-21 |
2006-08-08 |
Generex Pharmaceuticals Incorporated |
Methods of administering and enhancing absorption of pharmaceutical agents
|
|
EP1141008A1
(en)
|
1998-12-31 |
2001-10-10 |
Millennium Pharmaceuticals, Inc. |
Class ii cytokine receptor-like proteins and nucleic acids encoding them
|
|
JP2004522402A
(ja)
|
1999-06-02 |
2004-07-29 |
ジェネンテック・インコーポレーテッド |
同一のものをコードする分泌及び膜貫通ポリペプチドと核酸
|
|
US20050060101A1
(en)
|
1999-06-28 |
2005-03-17 |
Bevilacqua Michael P. |
Systems and methods for characterizing a biological condition or agent using precision gene expression profiles
|
|
CZ20021186A3
(cs)
|
1999-10-04 |
2002-11-13 |
Chiron Corporation |
Farmaceutické prostředky obsahující stabilizovaný kapalný polypeptid
|
|
KR100399156B1
(ko)
*
|
1999-11-19 |
2003-09-26 |
주식회사 엘지생명과학 |
α-인터페론의 용액제형
|
|
US6610286B2
(en)
|
1999-12-23 |
2003-08-26 |
Zymogenetics, Inc. |
Method for treating inflammation using soluble receptors to interleukin-20
|
|
AU783473B2
(en)
|
1999-12-23 |
2005-10-27 |
Zymogenetics Inc. |
Soluble interleukin-20 receptor
|
|
CA2406128A1
(en)
|
2000-04-07 |
2001-10-18 |
Ellis L. Kline |
Methods and compositions for treating neoplasms
|
|
US7015194B2
(en)
|
2000-05-10 |
2006-03-21 |
Novo Nordisk A/S |
Pharmaceutical composition comprising factor VIIa and anti-TFPI
|
|
JP5490972B2
(ja)
|
2000-08-04 |
2014-05-14 |
中外製薬株式会社 |
タンパク質注射製剤
|
|
DE60123998T2
(de)
|
2000-08-08 |
2007-09-06 |
Zymogenetics, Inc., Seattle |
Lösliche zcyctor 11 cytokinrezeptoren
|
|
JP5485489B2
(ja)
|
2000-08-11 |
2014-05-07 |
中外製薬株式会社 |
抗体含有安定化製剤
|
|
AU2002213441B2
(en)
|
2000-10-12 |
2006-10-26 |
Genentech, Inc. |
Reduced-viscosity concentrated protein formulations
|
|
CA2433933A1
(en)
|
2001-02-28 |
2002-09-12 |
Eli Lilly And Company |
Use of lp82 to treat hematopoietic disorders
|
|
EP1399472B1
(en)
|
2001-03-09 |
2009-06-03 |
ZymoGenetics, Inc. |
Soluble heterodimeric cytokine receptor
|
|
MXPA04000747A
(es)
|
2001-07-25 |
2004-07-08 |
Protein Desing Labs Inc |
Formulacion farmaceutica liofilizada estable de anticuerpos igg.
|
|
ES2629395T3
(es)
|
2001-10-04 |
2017-08-09 |
Genetics Institute, Llc |
Métodos y composiciones para modular la actividad de la interleucina-21
|
|
US7022289B1
(en)
|
2001-10-10 |
2006-04-04 |
The United States Of America As Represented By The Secretary Of The Army |
Chemical and biological sampling device and kit and method of use thereof
|
|
PT2308888T
(pt)
*
|
2001-11-14 |
2017-05-03 |
Janssen Biotech Inc |
Anticorpos anti-il-6, composições, métodos e utilizações
|
|
CA2467723C
(en)
|
2001-12-17 |
2011-09-27 |
Zymogenetics, Inc. |
Method for treating cervical cancer
|
|
CN101721362B
(zh)
|
2002-02-14 |
2018-07-03 |
中外制药株式会社 |
包含抗体的溶液制剂
|
|
SI1478394T1
(sl)
|
2002-02-27 |
2008-12-31 |
Immunex Corp |
STABILIZIRAN TNFR-Fc SESTAVEK Z ARGININOM
|
|
CA2481304A1
(en)
|
2002-03-27 |
2003-10-09 |
Patrick Hwu |
Method for treating cancer in humans
|
|
US20040009168A1
(en)
|
2002-04-05 |
2004-01-15 |
Elizabet Kaisheva |
Multidose antibody formulation
|
|
DK1531850T3
(da)
|
2002-06-07 |
2012-06-04 |
Zymogenetics Inc |
Anvendelse af 1L-21 og monoklonalt antistof til behandling af solide cancere
|
|
US7425618B2
(en)
|
2002-06-14 |
2008-09-16 |
Medimmune, Inc. |
Stabilized anti-respiratory syncytial virus (RSV) antibody formulations
|
|
US20040022792A1
(en)
|
2002-06-17 |
2004-02-05 |
Ralph Klinke |
Method of stabilizing proteins at low pH
|
|
CN1671741A
(zh)
|
2002-06-21 |
2005-09-21 |
拜奥根Idec公司 |
浓缩抗体的缓冲剂制剂及其使用方法
|
|
AU2003281528A1
(en)
|
2002-07-18 |
2004-02-09 |
Fabio Perini S.P.A. |
Storage unit for elongated products
|
|
US20040033228A1
(en)
|
2002-08-16 |
2004-02-19 |
Hans-Juergen Krause |
Formulation of human antibodies for treating TNF-alpha associated disorders
|
|
AU2003293543A1
(en)
*
|
2002-12-13 |
2004-07-09 |
Abgenix, Inc. |
System and method for stabilizing antibodies with histidine
|
|
DK2236154T3
(en)
|
2003-02-10 |
2018-06-25 |
Biogen Ma Inc |
IMMUNOGLOBULIN INFORMATION AND METHOD OF PREPARING IT
|
|
MXPA05010555A
(es)
*
|
2003-04-04 |
2006-03-09 |
Genentech Inc |
Formulaciones de proteina y anticuerpo de alta concentracion.
|
|
AR045056A1
(es)
|
2003-07-15 |
2005-10-12 |
Amgen Inc |
Anticuerpos anti-ngf humanos neutralizantes como inhibidores selectivos de la via de ngf
|
|
HUE026793T2
(en)
|
2003-10-01 |
2016-07-28 |
Kyowa Hakko Kirin Co Ltd |
A method for stabilizing an antibody and a stabilized solution-type antibody preparation
|
|
EP1712240B1
(en)
|
2003-12-25 |
2015-09-09 |
Kyowa Hakko Kirin Co., Ltd. |
Stable water-based medicinal preparation containing antibody
|
|
JP2008505192A
(ja)
|
2004-06-14 |
2008-02-21 |
メッドイミューン バクシーンズ，インコーポレイティド |
生物活性材料の高圧噴霧乾燥
|
|
AU2005299809B2
(en)
|
2004-10-22 |
2010-12-02 |
Zymogenetics, Inc. |
Anti-IL-22RA antibodies and binding partners and methods of using in inflammation
|
|
EP1856156A2
(en)
|
2005-02-08 |
2007-11-21 |
ZymoGenetics, Inc. |
Anti-il-20, anti-il-22 and anti-il-22ra antibodies and binding partners and methods of using in inflammation
|
|
US7525604B2
(en)
|
2005-03-15 |
2009-04-28 |
Naxellent, Llc |
Windows with electrically controllable transmission and reflection
|
|
DE602006020568D1
(de)
|
2005-07-02 |
2011-04-21 |
Arecor Ltd |
Stabile wässrige systeme mit proteinen
|
|
WO2007006858A2
(en)
|
2005-07-12 |
2007-01-18 |
Oy Jurilab Ltd |
Method for treatment of cardiovascular and metabolic diseases and detecting the risk of the same
|
|
AU2006295340B2
(en)
|
2005-08-05 |
2010-11-11 |
Amgen Inc. |
Stable aqueous protein or antibody pharmaceutical formulations and their preparation
|
|
EP1945814A2
(en)
|
2005-09-27 |
2008-07-23 |
Source MDX |
Gene expression profiling for identification monitoring and treatment of rheumatoid arthritis
|
|
WO2007038501A2
(en)
|
2005-09-27 |
2007-04-05 |
The Feinstein Institute For Medical Research |
Rheumatoid arthritis markers
|
|
KR101357685B1
(ko)
|
2005-11-21 |
2014-02-06 |
사노피 파스퇴르 리미티드 / 사노피 파스퇴르 리미떼 |
재조합 바이러스용 안정화 제형
|
|
BRPI0620316A2
(pt)
|
2005-12-21 |
2011-11-08 |
Wyeth Corp |
formulações de proteìnas com viscosidades reduzida e seus usos
|
|
WO2007074880A1
(ja)
|
2005-12-28 |
2007-07-05 |
Chugai Seiyaku Kabushiki Kaisha |
抗体含有安定化製剤
|
|
CA2638811A1
(en)
|
2006-02-03 |
2007-08-16 |
Medimmune, Llc |
Protein formulations
|
|
DE102006005094A1
(de)
|
2006-02-04 |
2007-08-09 |
Degussa Gmbh |
Titandioxid und Polycarboxylatether enthaltende Dispersion
|
|
TW200744634A
(en)
|
2006-02-21 |
2007-12-16 |
Wyeth Corp |
Methods of using antibodies against human IL-22
|
|
US20090128815A1
(en)
|
2006-03-15 |
2009-05-21 |
Koninklijke Philips Electronics N.V. |
Remote control pointing technology with roll detection
|
|
TW200806317A
(en)
|
2006-03-20 |
2008-02-01 |
Wyeth Corp |
Methods for reducing protein aggregation
|
|
JP4294082B2
(ja)
|
2006-03-23 |
2009-07-08 |
協和発酵キリン株式会社 |
ヒトトロンボポエチン受容体に対するアゴニスト抗体
|
|
JP2009531371A
(ja)
*
|
2006-03-28 |
2009-09-03 |
エフ．ホフマン−ラ ロシュ アーゲー |
抗ｉｇｆ−１ｒヒト・モノクローナル抗体製剤
|
|
EP1857559A1
(en)
|
2006-05-16 |
2007-11-21 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
A method for predicting responsiveness to TNF alpha blocking agents
|
|
CA2654794A1
(en)
|
2006-06-14 |
2007-12-21 |
Imclone Systems Incorporated |
Lyophilized formulations of anti-egfr antibodies
|
|
WO2007149814A1
(en)
|
2006-06-19 |
2007-12-27 |
Wyeth |
Methods of modulating il-22 and il-17
|
|
MX2008015830A
(es)
|
2006-06-30 |
2009-01-09 |
Novo Nordisk As |
Anticuerpos anti-nkg2a y usos de los mismos.
|
|
TW200831129A
(en)
|
2006-10-06 |
2008-08-01 |
Amgen Inc |
Stable formulations
|
|
EP2076287A2
(en)
|
2006-10-12 |
2009-07-08 |
Wyeth |
Methods and compositions with reduced opalescence
|
|
US20100267575A1
(en)
|
2006-10-17 |
2010-10-21 |
Childrens Hospital Medical Center |
Gene array technique for predicting response in inflammatory bowel diseases
|
|
JP2010508838A
(ja)
|
2006-11-09 |
2010-03-25 |
アンスティテュ ナシオナル ドゥ ラ サントゥ エ ドゥ ラ ルシェルシェ メディカル（イーエヌエスエーエールエム） |
ＴＮＦ−α遮断薬に対する治療応答性の予測方法
|
|
CL2007003583A1
(es)
|
2006-12-11 |
2008-07-18 |
Hoffmann La Roche |
Formulacion farmaceutica estable, parenteral, del anticuerpo contra el peptido beta amiloide (abeta); y uso de la formulacion para el tratamiento de la enfermedad de alzheimer.
|
|
CA2674608A1
(en)
*
|
2007-01-09 |
2008-07-17 |
Wyeth |
Anti-il-13 antibody formulations and uses thereof
|
|
EP2132343B1
(en)
|
2007-03-01 |
2012-08-29 |
Université Catholique de Louvain |
Method for the determination and the classification of rheumatic conditions
|
|
KR101087344B1
(ko)
|
2007-03-23 |
2011-11-25 |
파나소닉 주식회사 |
도전성 범프와 그 제조 방법 및 전자 부품 실장 구조체
|
|
CA2682292A1
(en)
|
2007-03-30 |
2008-10-09 |
Medimmune, Llc |
Aqueous formulation comprising an anti-human interferon alpha antibody
|
|
GB0707938D0
(en)
|
2007-04-25 |
2007-05-30 |
Univ Strathclyde |
Precipitation stabilising compositions
|
|
WO2008132176A2
(en)
|
2007-04-27 |
2008-11-06 |
Universite Catholique De Louvain |
Method for evaluating the response of an individual to tnf blocking therapy
|
|
US20100303813A1
(en)
|
2007-06-08 |
2010-12-02 |
Biogen Idec Ma Inc. |
Biomarkers for predicting anti-tnf responsiveness or non-responsiveness
|
|
US20090208492A1
(en)
|
2007-06-14 |
2009-08-20 |
Elan Pharmaceuticals, Inc. |
Lyophilized Immunoglobulin Formulations and Methods of Preparation
|
|
NZ595526A
(en)
|
2007-06-14 |
2013-03-28 |
Biogen Idec Inc |
Pharmaceutical composition comprising a vla-4 binding antibody, a phosphate buffer and a surfactant
|
|
US20090004189A1
(en)
|
2007-06-18 |
2009-01-01 |
Genentech, Inc. |
Biological markers predictive of rheumatoid arthritis response to b-cell antagonists
|
|
EP2170268A2
(en)
|
2007-06-25 |
2010-04-07 |
Amgen, Inc. |
Compositions of specific binding agents to hepatocyte growth factor
|
|
UA107557C2
(xx)
|
2007-07-06 |
2015-01-26 |
|
Композиція антитіла офатумумабу
|
|
EP2173163A4
(en)
|
2007-07-06 |
2010-12-08 |
Glaxosmithkline Llc |
ANTIBODY FORMULATIONS
|
|
JP2010534318A
(ja)
|
2007-07-20 |
2010-11-04 |
ナショナル インスティテュート フォー バイオプロセッシング リサーチ アンド トレーニング リミテッド |
癌および慢性炎症のグリコシル化マーカー
|
|
US20100261613A1
(en)
|
2007-07-26 |
2010-10-14 |
Michael Centola |
Methods for inflammatory disease management
|
|
WO2009070642A1
(en)
|
2007-11-28 |
2009-06-04 |
Medimmune, Llc |
Protein formulation
|
|
AU2008337517B2
(en)
|
2007-12-14 |
2014-06-26 |
Novo Nordisk A/S |
Antibodies against human NKG2D and uses thereof
|
|
RU2010138612A
(ru)
|
2008-02-20 |
2012-03-27 |
Джи2 ИНФЛЕММЕЙШН ПТИ ЛТД (AU) |
ГУМАНИЗИРОВАННЫЕ АНТИТЕЛА ПРОТИВ C5аR
|
|
WO2009120684A1
(en)
|
2008-03-25 |
2009-10-01 |
Medimmune, Llc |
Antibody formulation
|
|
EP2281000A2
(en)
|
2008-05-15 |
2011-02-09 |
Novo Nordisk A/S |
Antibody purification process
|
|
TWI451876B
(zh)
*
|
2008-06-13 |
2014-09-11 |
Lilly Co Eli |
聚乙二醇化之離脯胰島素化合物
|
|
BRPI0914916A2
(pt)
|
2008-06-30 |
2015-10-20 |
Novo Nordisk As |
anticorpos de interleucina-20 anti-humanos, assim como método de produção dos mesmos
|
|
UA112050C2
(uk)
*
|
2008-08-04 |
2016-07-25 |
БАЄР ХЕЛСКЕР ЛЛСі |
Терапевтична композиція, що містить моноклональне антитіло проти інгібітора шляху тканинного фактора (tfpi)
|
|
KR20110048536A
(ko)
|
2008-08-28 |
2011-05-11 |
와이어쓰 엘엘씨 |
자가면역 질병에서 ｉｌ－２２, ｉｌ－１７ 및 ｉｌ－１ 패밀리 시토킨의 용도
|
|
ES2531385T3
(es)
|
2008-09-19 |
2015-03-13 |
Hoffmann La Roche |
Formulación que comprende un anticuerpo contra la selectina P
|
|
EP2196476A1
(en)
|
2008-12-10 |
2010-06-16 |
Novartis Ag |
Antibody formulation
|
|
WO2010072691A1
(en)
|
2008-12-22 |
2010-07-01 |
Novo Nordisk A/S |
Antibodies against tissue factor pathway inhibitor
|
|
DK2414542T3
(da)
|
2009-03-30 |
2017-11-27 |
Tel Hashomer Medical Res Infrastructure & Services Ltd |
Fremgangsmåder til forudsigelse af klinisk forløb for og behandling af multipel sklerose
|
|
JP5996429B2
(ja)
|
2009-09-03 |
2016-09-21 |
ジェネンテック， インコーポレイテッド |
関節リウマチの治療、診断及びモニターするための方法
|
|
US8580528B2
(en)
|
2009-10-16 |
2013-11-12 |
Stichting Vu-Vumc |
Method for prognosticating the clinical response of a patient to B-lymphocyte inhibiting or depleting therapy
|
|
EP2488875A4
(en)
|
2009-10-16 |
2013-02-27 |
Mayo Foundation |
DETERMINATION RHEUMATOID ARTHRITIS
|
|
EP3409289B1
(en)
|
2010-02-26 |
2020-09-30 |
Novo Nordisk A/S |
Stable antibody containing compositions
|
|
RU2012153786A
(ru)
|
2010-05-28 |
2014-07-10 |
Ново Нордиск А/С |
Стабильные многодозовые композиции, содержащие антитело и консервант
|
|
CA2801107A1
(en)
|
2010-06-07 |
2011-12-15 |
F. Hoffman-La Roche Ag |
Gene expression markers for predicting response to interleukin-6 receptor-inhibiting monoclonal antibody drug treatment
|
|
US8603470B1
(en)
|
2012-08-07 |
2013-12-10 |
National Cheng Kung University |
Use of IL-20 antagonists for treating liver diseases
|